1809251-51-1
1809251-51-1
Chemical Structure
Abemaciclib-d5
Synonym(s): LY2835219-d5
- CAS No.: 1809251-51-1
- Formula:C27H27D5F2N8
- Molecular Weight:511.62
InChIKey: UZWDCWONPYILKI-RPIBLTHZSA-N
SMILES: CC(N1C(C)C)=NC(C1=CC(C2=C(C=NC(NC3=CC=C(CN4CCN(C([2H])(C([2H])([2H])[2H])[2H])CC4)C=N3)=N2)F)=C5)=C5F
Biological Activity: Abemaciclib-d5 (LY2835219-d5) is a deuterium labeled Abemaciclib (HY-16297A)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Abemaciclib-d5 | Abemaciclib-d5 (LY2835219-d5) is a deuterium labeled Abemaciclib (HY-16297A). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Abemaciclib (Standard) | 99.94% | Abemaciclib (Standard) is the analytical standard of Abemaciclib. This product is intended for research and analytical applications. Abemaciclib (LY2835219) is a selective and BBB-permeable CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Abemaciclib-d8 | 99.96% | Abemaciclib-d8 is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Abemaciclib | 99.97% | Abemaciclib (LY2835219) is a selective and BBB-permeable CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget. 2016 Mar 22;7(12):14803-13. [Content Brief]
- [2]. Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63. [Content Brief]
- [3]. Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825-37. [Content Brief]
